Bulletin
Investor Alert

June 18, 2022, 3:31 p.m. EDT

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the Firm

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Jun 18, 2022 (ACCESSWIRE via COMTEX) -- LOS ANGELES, CA / ACCESSWIRE / June 18, 2022 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofIntra-Cellular Therapies, Inc. ("Intra-Cellular" or "the Company") (NASDAQ: ITCI ) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

If you are a shareholder who suffered a loss, click here to participate .

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com , or by email at bschall@schallfirm.com .

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The Schall Law Firm

COMTEX_408893713/2457/2022-06-18T15:31:18

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.